MRFR Year End Sale
Mastitis Market Research Report - Forecast till 2030

Mastitis Market: Information by Type (Bovine {Contagious Mastitis, Environmental Mastitis and Opportunist Mastitis} and Human {Non-Infectious Mastitis and Infectious Mastitis}), Treatment (Bovine {Antibiotics and Vaccines} and Human {Pain Relievers and Antibiotics}), End User (Veterinary Centers and Hospital & Clinics) - Forecast till 2030

ID: MRFR/Pharma/3936-CR | July 2019 | Region: Global | 142 Pages         

Mastitis Market Speak to Analyst Request a Free Sample

Market overview


According to recent reports, the Mastitis Market size is predicted to grow at a compound annual growth rate of a CAGR of 16.20 % from 2021 to 2030, reaching USD 53,148.44 million. Breast cancer is caused by infections in the tissue with one or even both mammary glands located within the breast. It mainly strikes nursing women, and it is caused by a blocked or clogged duct system in the uterus. The infection of the mammary gland and udder tissue in bovines is caused by bacterial infiltration of the teat canal by a number of bacterial sources found on the farm. Mastitis may also develop as a consequence of chemical, physical, or thermal harm to the cow's udder.


The growing number of incidences of breast cancer, the expanding rate of pregnancies, and unsanitary barn conditions resulting in infectious mastitis in cattle around the world are all predicted to contribute to the market's expansion. However, although the Mastitis Market value is expected to develop, the lack of knowledge and difficulties in diagnosing breast cancer and mastitis as a result of their comparable symptoms is expected to limit its expansion.


This report contains all the information on the global Mastitis Market analysis and its strengths. In addition, the report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global Mastitis Market forecast for 2027 is also included in the report.


Covid 19 Analysis


The distribution network for goods used to treat bovine mastitis was unaffected by the COVID-19. Nonetheless, Lockdown and social distancing procedures have led to a decrease in the supply of medications in veterinary clinics. However, there seems to be no significant consequence on the supply chain network, as per a Zoetis report released in April 2020. The different firms have been working closely together to maintain the US Food and Drug Administration informed about the shortfall or disruptions in manufacturing.


Market Dynamic


Drivers


The rising prevalence of illness, the expansion in product releases for livestock healthcare, and technical improvements in medication research and development are some of the primary factors driving the rise of the bovine mastitis market growth.


Opportunities


One of the most pressing issues in the global dairy business is bovine mastitis. Dairy producers see their profits plummet as the number of animal deaths rises year after year. Tests, milk loss, animal health, labor, potential losses in dairy production, and treatments are all included in this cost. Producers are becoming more knowledgeable about the therapy of bovine mastitis, which is driving up the need for antibiotics.


Restraints


According to analysts, rising risks of resistance to antibiotics and a lack of public knowledge of the condition are predicted to restrain market growth throughout the forecast period.


Challenges


An undesirable impact associated with the therapy, a lack of knowledge in developing economies, and difficulty in diagnosis owing to symptoms identical to breast cancer might all provide challenges to the worldwide Mastitis market in the future.


Cumulative Growth Analysis


Mastitis has raised in importance in recent years the number to the increasing prevalence of breast cancer in the population. For example, according to the Breast Cancer Research Foundation, 266,120 new instances of aggressive breast cancer were detected in females in the United States in 2018. According to Cancer Research UK, about 11,563 women died from breast cancer in the United Kingdom in 2016, an increase from 2015. According to the World Cancer Research Fund International, Belgian women were reported to have the greatest rate of breast cancer in 2017. The fact that such a large number of people are affected by breast cancer will help to drive market expansion over the projection period.


Value Chain Analysis


According to the reports, the mastitis market has been divided into bovine mastitis and human mastitis. Furthermore, the Mastitis market has been divided into two categories based on the therapy used: bovine and human. In addition, the mastitis market has been segmented into two categories depending on the end-user: veterinary centres and hospitals & clinics.


In the case of bovines, unsanitary animal housing conditions are the primary driving force behind the market's expansion, resulting in the spreading of infectious mastitis among the animals in the herd. In addition, growing public knowledge of mastitis issues, efficient management of the disease, and the affordability of therapy are all contributing to the growth of the market in general.


Segmentation Overview


The market is segmented based on bovine mastitis, human mastitis, end-user, and region. The global mastitis market trends are expected to witness decent growth during the forecast period.


By Application


Based on the Application, the market is segmented into bovine and human.


By end-users


Based on the propulsion types, the market is segmented into veterinary centres and hospitals & clinics.


Global Mastitis Market Share, by Type, 2016 (%)
 Mastitis Market


Source: MRFR Analysis


Regional Analysis


According to the reports, based on geography, the mastitis market is segmented into four groups: the Americas, Europe; Asia-Pacific; and the Middle East and Africa. Americas is predicted to account for a significant portion of the global mastitis market. Several factors are projected to contribute to North America's market dominance, including a rising frequency of mastitis among the cattle population and an increased number of breast cancer in the area. During the projection period, Europe is estimated to account for the second-largest global market share. Improved health institutions, increased government measures to encourage healthy breastfeeding, and increasing healthcare spending are all factors contributing to the mastitis market outlook expansion in this area. According to Eurostat, Germany invested more than EUR 321 billion in 2014, which is a lot of money.


Because of the existence of quickly emerging economies such as China, India, and South Korea, the Asia-Pacific region is expected to be the fastest-growing area in the worldwide market. Furthermore, the large number of patients suffering from chronic illnesses and government measures to overhaul the healthcare system would contribute to the market's expansion. In addition, because of the cost and accessibility of healthcare in the Middle East and Africa, the mastitis market in these regions is likely to rise.


 


Asia-Pacific Mastitis Market Share, 2016 (%)  Mastitis Market


Source: MRFR Analysis


Competitive landscape


Creativity, project management, and acquisition and mergers were among the primary tactics businesses participating in the mastitis industry.


Major Key Players



  • Bayer AG (Germany)

  • Oncothyreon Inc (US)

  • OncoGenex (US)

  • Apthera Inc. (UK)

  • Zoetis Inc. (US)

  • Boehringer Ingelheim GmbH (Germany)

  • Merck Co. & Inc. (US)

  • Astellas Pharma Inc. (Japan)

  • Pfizer Inc. (US)

  • Novartis AG (Switzerland)

  • Sanofi SA (France)

  • Hoffmann-La Roche AG (Switzerland)


Report Overview


The following report comprises of –



  • Market overview 

  • Covid 19 Analysis

  • Market Dynamic

  • Drivers

  • Opportunities

  • Restraints 

  • Challenges

  • Cumulative Growth Analysis

  • Value Chain Analysis

  • Segmentation Overview 

  • By Application 

  • By End-Users

  • Regional Analysis

  • Competitive landscape


Recent Developments



  • A new Biological Development Centre (BDC) at Boehringer Ingelheim's research development locations in Biberach, Germany, was revealed in June 2018 with a 230-million-euro investment. The BDC will be the company's first BDC.

  • Tavocept, an experimental novel medication developed by BioNumerik Pharmaceuticals, was approved by the Food and Drug Administration in June 2017 for use in both cancer and non-oncology purposes.

  • Keytruda, developed by Merck & Co., was authorized by the FDA in May 2017 to treat adult and pediatric individuals with recently treated advanced or metastatic or metastatic solid tumors with high microsatellite instability (MSI-H) mismatch repair deficiency.


Market Segmentation


Mastitis Market, by Type



  • Bovine


    • Contagious Mastitis

    • Environmental Mastitis

    • Opportunist Mastitis


  • Human


    • Non-Infectious Mastitis

    • Infectious Mastitis



Mastitis Market, by Treatment



  • Bovine


    • Antibiotics

    • Vaccines




  • Human


    • Pain Relievers

    • Antibiotics



Mastitis Market, by End User



  • Veterinary Centers

  • Hospital & Clinics


Mastitis Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Saudi Arabia

    • United Arab Emirates

    • Kuwait

    • Oman

    • Qatar

    • Rest of Middle East




Report Scope:

Report Attribute/Metric Details
  Market Size

  • 2030: USD 53,148.44 Million
  • 2027: Significant Value
  •   CAGR   16.20% (2020-2030)
      Base Year   2019
      Forecast Period   2020-2030
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Treatment, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rising cases of breast cancer Increasing rate of pregnancy
  • Unhygienic barn conditions causing contagious mastitis in bovines


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Mastitis market projected to grow at approximately 16.20% CAGR during the assessment period (2020-2030).

    The valuation of the mastitis market is estimated to increase to USD 53,148.44 MN by the end of 2030.

    Increasing need for better treatments and government funding support for R&D are major tailwinds pushing the growth of the global mastitis market.

    North America holds the largest share in the global mastitis market, followed by Europe and the Asia Pacific, respectively.

    Novartis AG (Switzerland), Pfizer (U.S.), Oncogenex (U.S.), BioNumerik Pharmaceuticals (U.S.), Apthera Inc. (U.K), Oncothyreon Inc. (US), Bipar Sciences (U.S.), Astellas (Japan), Puma Biotechnology (U.S.), Eli Lilly and Company (U.S.), Sanofi S.A. (U.S.), AstraZeneca (UK), GlaxoSmithKline (U.K), F. Hoffmann-La Roche (Switzerland), Genentech (U.S), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries (Israel), Gilead Sciences, Inc. (U.S.), and Accord Healthcare, Inc. (U.S.), are some of the top players operating in the global mastitis market.

    Global Mastitis Market Competitive Landscape:


    The prominent players in the global mastitis market are Zoetis Inc., Merck Co. & Inc., Boehringer Ingelheim, Eli Lilly and Company, Bayer Animal Health, Astellas Pharma Inc., Sanofi S.A., AstraZeneca, Teva Pharmaceutical, F. Hoffmann-La Roche Ltd and others.


    Zoetis Inc. is the holds the largest share for the global mastitis market in 2017. The firm operates through the discovery, development, manufacture, and commercialization of animal health medicines and vaccines. For more than 60 years, the company has been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them.


    Merck Co. & Inc. holds second position in terms of market share in the global mastitis market in 2017. The company operates in the prescription medicines, vaccines, biologic therapies, and animal health products. The company’s operations are principally managed on a products basis and include four operating segments, which are pharmaceutical, animal health, healthcare services, and alliances. The pharmaceutical segment is the only reportable segment. The main focus of the company is to produce innovative medicines for the treatment of cancer.


    Boehringer Ingelheim holds third position in terms of market share in the global Mastitis market in 2017. The company is a highly focused research-driven pharmaceutical company. The main focus of the company is to cure diseases with the help of its core R&D expertise. It constantly works to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies, and on science itself.


    Astellas Pharma Inc is one of the top 20 global pharmaceutical research companies. Astellas is an expert in turning innovative science into medical solutions that bring value and hope to patients and their families. The main focus of the company is to keep the focus on addressing unmet medical needs and conducting business with ethics and integrity which enables to improve the health of people throughout the Americas and around the world.


    Bayer Animal Health operate in a wide range of areas of business including human and veterinary pharmaceuticals, consumer healthcare products, agricultural chemicals and biotechnology products, and high-value polymers. The pharmaceuticals division of the company focuses on prescription products in the areas of cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology, and ophthalmology.


    Zoetis Inc., Merck Co. & Inc., are the major companies for mastitis operating on a global scale. The lower market share of Bayer Animal Health can be attributed to fewer products offering, as compared to Microsurgical Instruments and other major players. Major players such as Astellas Pharma Inc., Sanofi S.A., AstraZeneca, Teva Pharmaceutical, F. Hoffmann-La Roche Ltd increase the level of competition in the global mastitis market, as these companies are expected to expand their product portfolios, with the help of other business units, to increase their market share.


    Intended Audience



    • Bovine mastitis drug manufacturers

    • Human mastitis drug suppliers

    • Poultry & research laboratories

    • Research and Development (R&D) Companies

    • Market Research and Consulting Service Providers

    • Potential Investors